Potential urine biomarkers for gestational hypertension and preeclampsia

Guo,Hong‑Xia; Zhu,Yan‑Bin; Wu,Cui‑Ping; Zhong,Mei; Hu,Shui‑Wang

doi:10.3892/mmr.2019.9911

Potential urine biomarkers for gestational hypertension and preeclampsia

Authors:
- Hong‑Xia Guo
- Yan‑Bin Zhu
- Cui‑Ping Wu
- Mei Zhong
- Shui‑Wang Hu
View Affiliations

Affiliations: Department of Obstetrics, Baoan Maternal and Child Health Hospital, Jinan University, Shenzhen, Guangdong 518102, P.R. China, Department of Obstetrics and Gynecology, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong 518100, P.R. China, Department of Obstetrics and Gynecology, Nan Fang Hospital of Southern Medical University, Guangzhou, Guangdong 510515, P.R. China, Department of Pathophysiology, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China
Published online on: January 30, 2019 https://doi.org/10.3892/mmr.2019.9911
Pages: 2463-2470
Copyright: © Guo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Differential proteomic technology was used to identify urine proteomic profile of gestational hypertension and preeclampsia. Urine samples were collected from 10 patients with gestational hypertension, 10 patients with mild preeclampsia, 10 patients with severe preeclampsia and 10 normal pregnancies and analyzed by 2‑D difference gel electrophoresis, then matrix assisted laser desorption ionization mass spectrometry was used to identify differential proteins. Subsequently, ELISA was used to verify the content variation of the identified proteins in 200 urine samples. In total, 30 differential proteins were identified. For prostaglandin‑H2 D‑isomerase (L‑PGDS), perlecan and other 15 proteins, the contents in patients with gestational hypertension were higher than that of normal pregnancies, but lower in mild and severe preeclampsia. By contrast, serum albumin and α‑1‑antitrypsin was lower in samples from patients with gestational hypertension and higher in patients with mild and severe preeclampsia compared with normal pregnancies. ELISA verified that the urinary concentration of L‑PGDS and perlecan were significantly lower in patients with preeclampsia than in normal pregnancies (P<0.05). Urine proteomics is a useful tool to identify potential biomarkers to distinguish between different types of hypertensive disorders in pregnancy. L‑PGDS and perlecan could potentially be used as markers to reflect the state of renal function, and may participate in the genesis and development of renal injury during preeclampsia.

View Figures

View References

1	Roberts JM: Pregnancy related hypertension. Maternal Fetal Medicine. Creasy RK and Resnik R: (4th). W.B Saunders. (Philadelphia, PA). 833–872. 1998.
2	Frampton GK, Jones J, Rose M and Payne L: Placental growth factor (alone or in combination with soluble fms-like tyrosine kinase 1) as an aid to the assessment of women with suspected pre-eclampsia: Systematic review and economic analysis. Health Technol Assess. 20:1–160. 2016. View Article : Google Scholar
3	Pasquali M, Serchi T, Planchon S and Renaut J: 2D-DIGE in proteomics. Methods Mol Biol. 1654:245–254. 2017. View Article : Google Scholar : PubMed/NCBI
4	Alban A, David SO, Bjorkesten L, Andersson C, Sloge E, Lewis S and Currie I: A novel experimental design for comparative two-dimensional gel analysis: Two-dimensional difference gel electrophoresis incorporating a pooled internal standard. Proteomics. 3:36–44. 2003. View Article : Google Scholar : PubMed/NCBI
5	Wei YS, Zheng YH, Liang WB, Zhang JZ, Yang ZH, Lv ML, Jia J and Zhang L: Identification of serum biomarkers for nasopharyngeal carcinoma by proteomic analysis. Cancer. 112:544–551. 2008. View Article : Google Scholar : PubMed/NCBI
6	Vuadens F, Benay C, Crettaz D, Gallot D, Sapin V, Schneider P, Bienvenut WV, Lémery D, Quadroni M, Dastugue B and Tissot JD: Identification of biologic markers of the premature rupture of fetal membranes: Proteomic approach. Proteomics. 3:1521–1525. 2003. View Article : Google Scholar : PubMed/NCBI
7	Roberts JM, August PA, Bakris G, Barton JR, Bernstein IM, Druzin M, Gaiser RR, Granger JP, Jeyabalan A, Johnson DD, et al: American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet Gynecol. 122:1122–1131. 2013.PubMed/NCBI
8	Anand S, Bench Alvarez TM, Johnson WE, Esplin MS, Merrell K, Porter TF and Graves SW: Serum biomarkers predictive of pre-eclampsia. Biomark Med. 9:563–575. 2015. View Article : Google Scholar : PubMed/NCBI
9	Kim SM, Cho BK, Kang MJ, Norwitz ER, Lee SM, Lee J, Park CW, Kim BJ, Jun JK, Park JS and Yi EC: Expression changes of proteins associated with the development of preeclampsia in maternal plasma: A case-control study. Proteomics. 16:1581–1589. 2016. View Article : Google Scholar : PubMed/NCBI
10	Kolialexi A, Mavreli D, Tounta G, Mavrou A and Papantoniou N: Urine proteomic studies in preeclampsia. Proteomics Clin Appl. 9:501–506. 2015. View Article : Google Scholar : PubMed/NCBI
11	Carty DM, Siwy J, Brennand JE, Zürbig P, Mullen W, Franke J, McCulloch JW, Roberts CT, North RA, Chappell LC, et al: Urinary proteomics for prediction of preeclampsia. Hypertension. 57:561–569. 2011. View Article : Google Scholar : PubMed/NCBI
12	Buhimschi IA, Zhao G, Funai E, Saade GR and Buhimschi C: Proteomics analysis of urine in preeclampsia (PE): A novel diagnosis for an old disease. Am J Obstet Gynecol. 193:S152005. View Article : Google Scholar
13	Blankley RT, Gaskell SJ, Whetton AD, Dive C, Baker PN and Myers JE: A proof-of-principle gel-free proteomics strategy for the identification of predictive biomarkers for the onset of pre-eclampsia. BJOG. 116:1473–1480. 2009. View Article : Google Scholar : PubMed/NCBI
14	Uehara Y, Makino H, Seiki K and Urade Y; L-PGDS Clinical Research Group of Kidney, : Urinary excretions of lipocalin-type prostaglandin D synthase predict renal injury in type-2 diabetes: A cross-sectional and prospective multicentre study. Nephrol Dial Transplant. 24:475–482. 2009. View Article : Google Scholar : PubMed/NCBI
15	Gerhardt T, Pöge U, Stoffel-Wagner B, Klein B, Klehr HU, Sauerbruch T and Woitas RP: Serum levels of beta-trace protein and its association to diuresis in haemodialysis patients. Nephrol Dial Transplant. 23:309–314. 2008. View Article : Google Scholar : PubMed/NCBI
16	Bacci MR, Cavallari MR, de Rozier-Alves RM, Alves Bda C and Fonseca FL: The impact of lipocalin-type-prostaglandin-D-synthase as a predictor of kidney disease in patients with type 2 diabetes. Drug Des Devel Ther. 22:3179–3182. 2015.
17	Saito S, Tsuda H and Michimata T: Prostaglandin D2 and reproduction. Am J Reprod Immunol. 47:295–302. 2002. View Article : Google Scholar : PubMed/NCBI
18	Gubbiotti MA, Neill T and Iozzo RV: A current view of perlecan in physiology and pathology: A mosaic of functions. Matrix Biol. 57-58:285–298. 2017. View Article : Google Scholar : PubMed/NCBI
19	Smith S and Hassell JR: Focus on molecules: Perlecan (HSPG2). Exp Eye Res. 83:471–472. 2006. View Article : Google Scholar : PubMed/NCBI
20	Conde-Knape K: Heparan sulfate proteoglycans in experimental models of diabetes: A role for perlecan in diabetes complications. Diabetes Metab Res Rev. 17:412–421. 2001. View Article : Google Scholar : PubMed/NCBI